GLP-1 Drugs and Stop-Loss Pricing: What Every Underwriter Needs to Know in 2026
Twelve percent of Americans have now used a GLP-1 drug for weight loss. In 2024, that number was closer to five percent. The velocity of adoption is not slowing down. For stop-loss underwriters, this isn’t a trend to watch. It’s a live underwriting variable that is already affecting claims and pricing — and most rating models were not built for it.
This article explains what GLP-1 drugs actually cost, how they affect specific and aggregate stop-loss exposure, and what underwriters can do to price this risk accurately without overcorrecting.
What GLP-1 Drugs Actually Cost a Self-Funded Plan
The most prescribed GLP-1s — Wegovy, Zepbound, and Ozempic — carry list prices between $900 and $1,400 per month. For a member on one of these drugs for a full plan year, gross drug cost can reach $15,000 to $25,000 annually before rebates. Rebates matter, but they’re inconsistent. Large groups with strong PBM contracts may see net costs of $8,000–$12,000 per member annually. Smaller self-funded groups with limited PBM leverage may see $14,000 or more.
At a 200-life group, if just 3% of members are on GLP-1 therapy — a conservative estimate given national adoption rates — that’s 6 members. At $12,000 net cost per member, that’s $72,000 in incremental pharmacy spend that wasn’t in last year’s experience data.
$72,000+
Estimated annual GLP-1 impact on a 200-life group at 3% utilisation — before factoring in medical trend or coverage expansion
How GLP-1 Exposure Flows Into Stop-Loss Claims
For most stop-loss policies, pharmacy spend does count toward specific deductible accumulation — though contract language varies. This is the first thing to verify. If your policy integrates Rx with medical, GLP-1 costs are directly relevant to specific claim triggers. If the policy is medical-only, they’re still relevant to aggregate exposure through the downstream medical effect.
That downstream effect matters more than it might seem. GLP-1 drugs are now being studied — and prescribed — for cardiovascular risk reduction, sleep apnea, kidney disease, and metabolic syndrome. A member who starts on Ozempic for weight loss may subsequently avoid a bariatric surgery, a cardiac event, or a diabetes diagnosis. That’s a potential claims reduction. But it’s a 2–3 year horizon. In the current plan year, the drug cost is real and immediate.
The underwriting timing mismatch is the core problem: the cost is front-loaded, the benefit is deferred.
Three Categories of GLP-1 Risk for Stop-Loss Underwriters
Medical Trend Volatility
A member who combines GLP-1 therapy with a pre-existing condition — Type 2 diabetes, cardiovascular disease, or metabolic syndrome — can produce a specific claim that exceeds the deductible on drug spend alone. As of 2026, specific attachment points for midsize groups typically range from $100,000 to $250,000. GLP-1 costs alone won’t breach that threshold for most claimants, but they do add a meaningful tail to high-acuity members.
The aggregate creep
Even where no single member reaches the specific deductible, GLP-1 adoption across a group raises aggregate expected claims. A group that was 108% of aggregate corridor last year may be 115% this year if GLP-1 adoption jumped from 1% to 4% of covered lives. This is the silent risk — it doesn’t trigger a specific claim alarm, but it quietly degrades aggregate performance.
The plan design wildcard
The group that didn’t cover GLP-1 drugs last year might cover them this year. Plan design changes mid-contract are standard in self-funded arrangements. This is one symptom of a broader shift — the product complexity explosion reshaping how underwriters must approach group health risk. If your underwriting model uses prior year experience as the base, it may significantly underweight a group that expanded GLP-1 coverage for 2026. Underwriters need to ask this question explicitly at submission.
What Underwriters Should Be Doing Differently Right Now
The erosion of competitive advantage is often invisible until it shows up in the year-end loss ratio. If your underwriters are still “data janitors,” your moat is drying up.
The question for leadership is no longer about “improving efficiency.” The real question is: “Is our underwriting function structured as a durable asset, or is it a bottleneck that is quietly eroding our market share?”
In the fully insured group medical market, your underwriting workflow is your fortress. It’s time to stop treating it like a utility and start treating it like the strategic weapon it is.
Ask about GLP-1 coverage at submission — not as a checkbox, but as a line item in the plan design review
Request prior year pharmacy trend data separately from medical. A group with 18% pharmacy trend and 6% medical trend tells a very different story than the blended number
Adjust aggregate corridor assumptions for groups with above-average GLP-1 exposure. The 110% corridor standard was calibrated before GLP-1 adoption reached current levels
Flag groups with a high proportion of members aged 45–65 and female, where GLP-1 adoption is significantly above the national average per RAND 2025 data
Consider whether your lasering criteria need updating — a member actively on a high-cost GLP-1 regimen is a known, quantifiable risk that can be priced at the individual level
The Rating Model Problem
The deeper issue for stop-loss carriers is that most rating models were calibrated on historical experience data that predates the GLP-1 adoption curve. A model trained on 2021–2023 experience underweights pharmacy trend by definition. This isn’t an argument for re-running your entire actuarial model. It’s an argument for applying a manual adjustment factor for GLP-1 exposure on groups where utilisation is above baseline — and building that factor into your rules engine rather than leaving it to individual underwriter judgment.
When underwriting decisions are made case by case without a systematic adjustment, you get pricing variance. Two underwriters looking at similar groups with similar GLP-1 exposure may arrive at materially different specific rates. That’s a governance problem as well as an accuracy problem.
The Bottom Line
GLP-1 drugs are not going away. The pipeline of new indications is expanding, and the White House’s agreement with Eli Lilly and Novo Nordisk to lower prices for Medicare and Medicaid will likely accelerate adoption further. Stop-loss underwriters who build systematic GLP-1 risk adjustment into their rating workflow now will be better positioned than those who treat it as a case-by-case exception.
The data is available. The methodology is not complicated. What’s required is the operational discipline to apply it consistently — and the system infrastructure to do so at scale.
With DataHub SmartRules™ Engine, GLP-1 loading factors are automatically applied based on your company’s predefined rules. Every underwriter follows the same logic, so submissions stay consistent, there’s a clear audit trail, and no manual re-entry or pricing variance.
Turn This Into a Repeatable Process
Most teams understand the GLP-1 risk. The gap is applying it consistently across every submission.
We’ve created a GLP-1 underwriting checklist you can use to standardize how your team evaluates and prices this exposure — before it shows up in your loss ratio.